{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:43:43Z","timestamp":1791546223178,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.chest.2022.06.042","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T21:30:57Z","timestamp":1657747857000},"page":"1360-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-4787","authenticated-orcid":false,"given":"Sheryl","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather B.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Z.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demosthenes G.","family":"Papamatheakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-9930","authenticated-orcid":false,"given":"Mona","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2022.06.042_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2022.06.042_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2022.06.042_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02310-2017","article-title":"Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension","volume":"51","author":"Hjalmarsson","year":"2018","journal-title":"Eur Respir J"},{"issue":"25","key":"10.1016\/j.chest.2022.06.042_bib4","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2022.06.042_bib5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.31.12.1461","article-title":"A\u00a0passion for P450s (remembrances of the early history of research on cytochrome P450)","volume":"31","author":"Estabrook","year":"2003","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.chest.2022.06.042_bib6","first-page":"263","article-title":"Basic review of the Cytochrome P450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J\u00a0Adv Pract Oncol"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.18773\/austprescr.2001.007","article-title":"Cytochrome P450 drug interactions: are they clinically relevant?","volume":"24","author":"Martin","year":"2001","journal-title":"Aust Prescr"},{"issue":"9","key":"10.1016\/j.chest.2022.06.042_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/00002018-200528090-00004","article-title":"The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions","volume":"28","author":"DuBuske","year":"2005","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.chest.2022.06.042_bib9","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"issue":"suppl 14","key":"10.1016\/j.chest.2022.06.042_bib10","doi-asserted-by":"crossref","first-page":"S1767","DOI":"10.21037\/jtd.2019.09.14","article-title":"Pharmacotherapy for pulmonary arterial hypertension","volume":"11","author":"Parikh","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.chest.2022.06.042_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.chest.2022.06.042_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mcp.2002.122473","article-title":"In\u00a0vivo and in\u00a0vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide","volume":"71","author":"van Giersbergen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.chest.2022.06.042_bib13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/0091270011423662","article-title":"Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"52","author":"Venitz","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.chest.2022.06.042_bib15","series-title":"Letaris (ambrisentan) package insert","year":"2019"},{"issue":"12","key":"10.1016\/j.chest.2022.06.042_bib16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/11539110-000000000-00000","article-title":"Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study","volume":"30","author":"Harrison","year":"2010","journal-title":"Clin Drug Invest"},{"issue":"6","key":"10.1016\/j.chest.2022.06.042_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1753465812458014","article-title":"An update on the use of ambrisentan in pulmonary arterial hypertension","volume":"6","author":"D\u2019Alto","year":"2012","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"10.1016\/j.chest.2022.06.042_bib18","first-page":"E824","article-title":"Endothelin receptor antagonists: status quo and future perspectives for targeted therapy","volume":"9","author":"Enevoldsen","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"10","key":"10.1016\/j.chest.2022.06.042_bib19","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.3390\/ijms22105146","article-title":"Pseudoephedrine\u2014benefits and risks","volume":"22","author":"G\u0142owacka","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.chest.2022.06.042_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","article-title":"Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects","volume":"52","author":"Atsmon","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.chest.2022.06.042_bib22","series-title":"CCDS. Janssen Research & Development, LLC. EDMS-ERI-205905239","year":"2020"},{"issue":"3","key":"10.1016\/j.chest.2022.06.042_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14740338.2014.859674","article-title":"Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension","volume":"13","author":"Dingemanse","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","article-title":"Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist","volume":"14","author":"Bruderer","year":"2012","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.chest.2022.06.042_bib25","first-page":"749","article-title":"Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"39","author":"Khaybullina","year":"2014","journal-title":"Pharm Ther"},{"issue":"8567","key":"10.1016\/j.chest.2022.06.042_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(87)91481-4","article-title":"Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium","volume":"2","author":"Radomski","year":"1987","journal-title":"Lancet"},{"issue":"9A","key":"10.1016\/j.chest.2022.06.042_bib27","doi-asserted-by":"crossref","first-page":"47M","DOI":"10.1016\/S0002-9149(03)00075-4","article-title":"Cardiovascular effects of tadalafil in patients on common antihypertensive therapies","volume":"92","author":"Kloner","year":"2003","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0895-7061(00)01177-8","article-title":"Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group","volume":"14","author":"Kloner","year":"2001","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.chest.2022.06.042_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","article-title":"The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction","volume":"45","author":"Gupta","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.chest.2022.06.042_bib31","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.chest.2022.06.042_bib32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.chest.2022.06.042_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0090-9556(24)15055-6","article-title":"In\u00a0vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions","volume":"28","author":"Warrington","year":"2000","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"2","key":"10.1016\/j.chest.2022.06.042_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/bpb.b14-00566","article-title":"Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation","volume":"38","author":"Takahiro","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.chest.2022.06.042_bib36","series-title":"Cialis (tadalafil) tablets drug approval package","year":"2003"},{"key":"10.1016\/j.chest.2022.06.042_bib37","doi-asserted-by":"crossref","unstructured":"Galie N, Muller K, Scalise AV, Grunig E. Patent plus: a blinded, randomised and extension study of riociguat plus sildenafil in PAH [published online ahead of print February 5, 2015]. Eur Respir J. https:\/\/doi.org\/10.1183\/09031936.00105914.","DOI":"10.1183\/09031936.00105914"},{"issue":"23","key":"10.1016\/j.chest.2022.06.042_bib38","first-page":"2268","article-title":"Authors of CHEST-1 and PATENT-1. Riociguat for pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2022.06.042_bib39","series-title":"Adempas package insert","year":"2017"},{"issue":"5","key":"10.1016\/j.chest.2022.06.042_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-015-0337-4","article-title":"Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in healthy young Chinese male non-smokers and smokers: results of a randomized, double-blind, placebo-controlled study","volume":"55","author":"Zhao","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.chest.2022.06.042_bib41","first-page":"382","article-title":"Role of prostacyclin in pulmonary hypertension","volume":"2014","author":"Mitchell","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","article-title":"Examination of 209 drugs for inhibition of cytochrome P450 2C8","volume":"45","author":"Walsky","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.chest.2022.06.042_bib43","series-title":"Orenitram (treprostinil) extended release tablets package insert","year":"2021"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bcp.14365","article-title":"Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects","volume":"87","author":"Axelsen","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.chest.2022.06.042_bib45","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/bcp.13379","article-title":"Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects","volume":"83","author":"Bruderer","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.chest.2022.06.042_bib46","series-title":"Uptravi (selexipag) package insert","year":"2021"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.chest.2022.06.042_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","article-title":"Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A","volume":"28","author":"Ma","year":"2000","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"10.1016\/j.chest.2022.06.042_bib50","first-page":"109","article-title":"Comparison of nifedipine alone and with diltiazem or verapamil in hypertension","volume":"28","author":"Saseen","year":"1996","journal-title":"Hypertens Dallas Tex 1979"},{"issue":"7237","key":"10.1016\/j.chest.2022.06.042_bib51","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/bmj.320.7237.768","article-title":"Human error: models and management","volume":"320","author":"Reason","year":"2000","journal-title":"BMJ"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222012223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222012223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:45:01Z","timestamp":1757925901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222012223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0012369222012223"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.06.042","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}